Your browser doesn't support javascript.
loading
Durability and correlates of vaccine protection against Zika virus in rhesus monkeys.
Abbink, Peter; Larocca, Rafael A; Visitsunthorn, Kittipos; Boyd, Michael; De La Barrera, Rafael A; Gromowski, Gregory D; Kirilova, Marinela; Peterson, Rebecca; Li, Zhenfeng; Nanayakkara, Ovini; Nityanandam, Ramya; Mercado, Noe B; Borducchi, Erica N; Chandrashekar, Abishek; Jetton, David; Mojta, Shanell; Gandhi, Priya; LeSuer, Jake; Khatiwada, Shreeya; Lewis, Mark G; Modjarrad, Kayvon; Jarman, Richard G; Eckels, Kenneth H; Thomas, Stephen J; Michael, Nelson L; Barouch, Dan H.
Afiliação
  • Abbink P; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Larocca RA; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Visitsunthorn K; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Boyd M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • De La Barrera RA; Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
  • Gromowski GD; Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
  • Kirilova M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Peterson R; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Li Z; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Nanayakkara O; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Nityanandam R; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Mercado NB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Borducchi EN; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Chandrashekar A; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Jetton D; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Mojta S; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Gandhi P; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • LeSuer J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Khatiwada S; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Lewis MG; Bioqual Inc., Rockville, MD 20852, USA.
  • Modjarrad K; Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
  • Jarman RG; Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
  • Eckels KH; Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
  • Thomas SJ; Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
  • Michael NL; Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
  • Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. dbarouch@bidmc.harvard.edu.
Sci Transl Med ; 9(420)2017 Dec 13.
Article em En | MEDLINE | ID: mdl-29237759
ABSTRACT
An effective Zika virus (ZIKV) vaccine will require long-term durable protection. Several ZIKV vaccine candidates have demonstrated protective efficacy in nonhuman primates, but these studies have typically involved ZIKV challenge shortly after vaccination at peak immunity. We show that a single immunization with an adenovirus vector-based vaccine, as well as two immunizations with a purified inactivated virus vaccine, afforded robust protection against ZIKV challenge in rhesus monkeys at 1 year after vaccination. In contrast, two immunizations with an optimized DNA vaccine, which provided complete protection at peak immunity, resulted in reduced protective efficacy at 1 year that was associated with declining neutralizing antibody titers to subprotective levels. These data define a microneutralization log titer of 2.0 to 2.1 as the threshold required for durable protection against ZIKV challenge in this model. Moreover, our findings demonstrate that protection against ZIKV challenge in rhesus monkeys is possible for at least 1 year with a single-shot vaccine.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / Zika virus / Infecção por Zika virus Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Sci Transl Med Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / Zika virus / Infecção por Zika virus Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Sci Transl Med Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos